Reimbursement Review Reports

( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.


Brand Name Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Admelog Insulin lispro Cancelled
Komboglyze Saxagliptin + metformin Diabetes Mellitus, Type 2 Withdrawn Jun 6, 2013
Entuzity KwikPen human insulin Diabetes mellitus Active Jan 27, 2021
Increlex mecasermin Severe primary insulin-like growth factor-1 deficiency Active Jun 14, 2021
Beleodaq Belinostat Withdrawn Jun 29, 2018
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Withdrawn Jul 4, 2019
TBC etonogestrel Prevention of pregnancy Withdrawn Sep 26, 2019
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn Nov 3, 2006
Xeomin incobotulinumtoxin A Chronic sialorrhea associated with neurological disorders Active Feb 26, 2021
Darzalex daratumumab Llight chain (AL) amyloidosis Active Jul 15, 2021